anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a pilot RCT, and the primary outcomes of this study are: 1) to test the feasibility and acceptability of the crowdsourced intervention, and 2) to pilot the preliminary impact of crowdsourced PS intervention in promoting HIV testing among partners of the newly identified HIV cases. In addition, this pilot RCT aimed to collect preliminary data for the designing of a full RCT, which aimed to measure the efficacy of the crowdsourced PS intervention in promoting PS. Thus, the sample size of this study is not designed and will be not powered enough to test the difference between the two arms. However, with a sample size of 120 (80 for intervention arm and 40 for the control arm, respectively), this pilot study would be able to observe the differences between the two arms and collect preliminary data for adequate sample size calculation of a full RCT. With a sample size of 120 (ratio of 2:1), alpha=0.05, power=0.80, and the partner return rate in the conventional PS arm is 30% (around 31% in 2016 in Guangzhou), the minimal detectable effect size would be 26.7% for this pilot study.

Data analyses: For the primary outcomes of feasibility and acceptability of the intervention: this will be analyzed through descriptive analysis to assess the feedback on the feasibility and acceptability of the crowdsourced PS intervention at baseline and the follow-up survey. For the primary outcome of the proportion of partners returning for HIV testing within 2 months of the index participant's enrolment in the study, log-binomial regression (generalized linear model with binomial distribution and log link) will be used to calculate 95% confidence intervals for the proportion of notifiable partners visiting by arm. Risk differences and risk ratios will also be calculated in these models. As this study is a pilot RCT, adjustment for covariates is not necessary and will not be conducted in the primary analysis. In secondary analyses, pre-specified potential confounding variables will be adjusted that might bias the estimate if not accounted for (e.g. index age, index marital status). If a partner reports more than one index referred him, he will be counted as a returning partner for each identified index.

Subgroup analyses will be performed by partner sex, partner type (e.g. main male partner vs. casual male partner) and sexual orientation. Time to presentation will also be assessed among all notifiable partners using Cox proportional hazards with a robust variance estimator. In the time-to-event analyses, censoring will occur at the end of 2-months. Note that for the primary outcome, the assumption is that any partner without an identifiable record at the community center or in the centralized electronic medical record (EMR) did not present for HIV testing. Therefore, this study assumes no missing outcome data. Sensitivity analyses will be conducted using alternative definitions of presentation for testing, including using the self-reported data from index cases and partners. For count variables expressed as the mean number of partners, the investigators will use either Poisson regression or negative binomial regression if overdispersion is identified.
PURPOSE:To provide the titled base film having increased drug contente, by using a copolymer resin of ethylene and an unsaturated carboxylic acid, etc. to at least one of the outermost layers of a mono- or multi-layer film, and adding a drug component to the layer. CONSTITUTION:A copolymer resin or ethylene and an unsaturated carboxylic acid or its derivative, or a vinyl ester (e.g., ethylene-methacrylic acid copolymer) is used as at least one of the outermost layers of a mono- or multi-layer film, and a drug component (e.g. dl-camphor, l-menthol, etc.) as a component of the layer to obtain the objective base film for the anti-inflammatory and analgesic plaster. The amount of the drug component adsorbed and retained in the resin can be controlled by adjusting the content of the carboxylic acid or carboxylic acid ester in the copolymer layer. The content of the carboxylic acid, etc. is preferably about 5-30%, and the drug component adsorbed and retained in the resin layer can be increased by increasing the content of the carboxylic acid etc.
PURPOSE:To obtain a rapidly breakable hydrous foaming agent which needs no vibration when used and is excellent in low-temp. stability, by mixing a silicone oil with an electron acceptor oil and filling an aerosol container having a particular valve with the mixture together with a propellant. CONSTITUTION:An anhydrous foaming agent is prepd. by enclosing a stock solution contg. a silicone oil, an electron acceptor oil and a propellant in a pressure-resistant can provided with a valve having a stem diameter of 0.33-0.61mm, a housing port diameter of 0.64-2.06mm and a spout having a nozzle area of 2.5-30mm<2>. It is pref. to prepare the above anhydrous foaming agent by blending 5-50wt% silicone oil, 30-80wt% oil, and 15-35wt% propellant. A preferable example of the oil includes fatty acid esters, particularly a triglyceride of a fatty acid.
NabPE+Sluritumab group（Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serulizumab 4.5mg/Kg ivgtt on Day 3）every 3 weeks for 6 cycles. Then paticipants will receive surgery and Serulizumab will be given as monotherapy every 3 weeks up to 6 months from the begining of the treatment.
The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
<P>PROBLEM TO BE SOLVED: To provide an artificial tooth stabilizer which scarcely adheres to fingers to give an excellent sense of use.  <P>SOLUTION: This artificial tooth stabilizer contains low polymerization degree vinyl acetate resin having an average polymerization degree of 600 to 900, middle polymerization degree vinyl acetate resin having an average polymerization degree of 1,000 to 2,000, and high polymerization degree vinyl acetate resin having an average polymerization degree of 4,000 to 7,000 as the main components of vinyl acetate resin. The amount of the compounded vinyl acetate resin is preferably 30 to 80 wt. %. The compounding ratio of the low polymerization degree vinyl acetate resin, the middle polymerization degree vinyl acetate resin, and the high polymerization degree vinyl acetate resin as the vinyl acetate resin is preferably 300 to 600: 300 to 600: 1 to 8.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Patients in the dance-therapy group will attend a weekly session of dance-therapy between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
The nanotechnology that is being developed with silver and its applications has a great commercial future. However, in many cases the colloidal silver solutions have impurities produced by the chemical production method; these compounds such as Br and Cl can cause toxic effects. In many products the silver concentration cannot reach the desired values, because increasing the silver concentration means increasing the toxin dose. In the present invention an original production method of high purity aqueous silver solutions is presented (non-toxic impurities). In the present invention, a second innovation is reported. These particles are: icosahedron, decahedron and platelets with FCC or HCP type (111) surfaces. These surfaces are the most active to destroy the bacteria, fungi and virus membranes. These particles have a controlled shape and size. The third innovation is that the solutions have a higher concentration of silver ions and positively charged nanoparticles, causing them to be attracted to bacteria, fungi and viruses, increasing the antibacterial activity. This is achieved by injecting oxygen into the nanoparticle solution for 15 minutes. Uncoated silver nanoparticles with faces (111) and charged species, is a highly efficient antibacterial, antiviral and fungicide, with a high spectrum and with an enormous potential for the treatment of nosocomial infections. This technology was applied to develop new products such as disinfectant solutions with silver nanoparticles, suture threads with silver nanoparticles, medical bandages and curation gauzes with silver nanoparticles, as well as, silver nanoparticles supported on BP clay, montmorillonite and clinoptilolite. The particles are also embedded in polymers such as polyethylene, PMMA, chitosan and others to produce antibacterial catheters, all of them, with an antibacterial and antiviral effect. The properties of these particles that make this an original patent, is that the surface is completely free of toxic substances like Bromine, commonly present in the extra components of the solution. An additional advantage is the size control of the particle. This is an important condition for toxicity free applications.
An individually randomised, open label, non-inferiority trial of ciprofloxacin versus an aminoglycoside and ciprofloxacin in patients with bubonic plague. We are using a non-inferiority design since the overall cure rate for bubonic plague without septicaemia with streptomycin is approximately 95%. As a result, demonstrating superiority would be unnecessary and impractical given the sample size that would be required. Our aim is therefore to demonstrate that ciprofloxacin alone is not more than 15% inferior to an aminoglycoside followed by ciprofloxacin. (15% is the non-inferiority margin in our study). We will recruit patients with a clinical suspicion of bubonic plague, but the size of our sample is powered based on an intention to treat infected patients sample size of 190, where infected is defined as a confirmed or probable case of bubonic plague. As a result the total number of patients to be enrolled will be higher than 190. We estimate that we will need to recruit approximately 600 patients with bubonic plague to achieve a sample size of 190 confirmed/probable bubonic plague patients. However, to mitigate risks of being under-powered we will propose to recruit for three full seasons with a minimum target of 190 confirmed/probable cases. Should we achieve the target of 190 confirmed/probable bubonic plague cases before the end of the final transmission season, we will nevertheless continue to recruit until the end of the season to retain power in the event of different treatment success percentages and to allow us to increase precision.

We will also recruit and collect data on patients with pneumonic plague, who will be enrolled in to a parallel observational cohort.
Many studies have shown that an increase in potassium through the diet or through potassium pills helps to lower blood pressure. Also, the amount of oral potassium taken can improve how well the participants blood vessels work. These studies have focused on potassium given in the form of a pill. The investigators are interested in the effect of potassium consumed through food sources and how it will effect arterial health and blood pressure. The world health organization (WHO) recommends a K⁺ intake of at least 3510 mg/day from food for adults, excluding those with impaired K⁺ excretion. In this study the investigators aim to provide approximately 75% (approximately 2000 mg) of the total daily recommended intake for potassium in one meal. The investigators do not know whether dietary potassium (not pill form) will acutely improve the arterial health and if it will cause a decrease in blood pressure. The investigators hypothesis to see an improvement in vascular function following a high potassium meal compared to a low potassium meal.
A gene therapeutic agent for preventing and treating lung cancer using transmission of aerosol gene is provided to reduce the activation of Akt1 and induce apoptosis in a cancer cell through a system in which the aerosol of polyester amine/Akt1 siRNA complex is inhaled via nose. A gene therapeutic agent for preventing and treating lung cancer makes a lung tumor cell contact with reaction agent and gene carrier which reduces Akt1 activation. The reaction agent is siRNA, antisense molecule, antagonist, ribozyme, inhibitor, peptide or small molecule. A gene carrier is a polyester amine. The contract comprises aerosol transfer or transfer using liposome, nano liposome, ceramide containing nano liposome, proteosome, nano particle, calcium phosphorous-silicate nano particle, calcium phosphate nano particle, silicon dioxide nano particulate, nano crystalline corpuscle, semiconductor nano particle, poly(D-arginine), nano dendrimer, virus, and calcium phosphate nucleotide-mediated nucleotide. The reaction agent and gene carrier form complex. The pharmaceutical composition for preventing and treating lung cancer comprises gene therapeutic agent and carrier.
The invention relates to a preparation method for extractive of Korean pine nut film coating with antioxidation effect. The preparation method is characterized in that every 1g antioxidative Korean pine nut film coating extractive is prepared from 0.05-5kg Korean pine nut film coating. The preparation method includes specific following steps: vacuum concentration of ethanol extractive; suction filtration; and vacuum concentration of acetone extractive. The preparation method prepares the ethanol extractive and the acetone extractive from waste Korean pine nut film coating, and the obtained extractive has outstanding radical scavenging activity and iron ion reduction capability. The extractive of Korean pine nut film coating is a novel and effective natural antioxidative component with plant-origin. The preparation method for the extractive of Korean pine nut film coating has simple operation and stable effect, and has advantage of realizing industrial production.
The group will be given Thiele Massage twice a week for 4 weeks. Thiele massage will be done with a stripping motion in the direction of the pelvic floor muscle fibers. Approximately 15-20 repetitions will be applied to each of the pelvic floor muscle groups for 30 minutes.
Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
Viruses are a key component of the colon microbiome, but the relationship between virome and colorectal cancer (CRC) remains poorly understood. We seek to identify alterations in the viral community that is characteristic of CRC and examine if they persist after surgery. Forty-nine fecal samples from 25 non-cancer (NC) individuals and 12 CRC patients, before and 6-months after surgery, were collected for metagenomic analysis. The fecal virome of CRC patients demonstrated an increased network connectivity as compared to NC individuals. Co-exclusion of influential viruses to bacterial species associated with healthy gut status was observed in CRC, suggesting an altered virome induced a change in the healthy gut bacteriome. Network analysis revealed lower connectivity within the virome and trans-kingdom interactions in NC. After surgery, the number of strong correlations decreased for trans-kingdom and within the bacteria and virome networks, indicating lower connectivity within the microbiome. Some co-occurrence patterns between dominant viruses and bacteria were also lost after surgery, suggesting a possible return to the healthy state of gut microbiome. Microbial signatures characteristic of CRC include an altered virome besides an altered bacterial composition. Elevated viral correlations and network connectivity were observed in CRC patients relative to healthy individuals, alongside distinct changes in the cross-kingdom correlation network unique to CRC patients. Some patterns of dysbiosis persist after surgery. Future studies should seek to verify if dysbiosis truly persists after surgery in a larger sample size with microbiome data collected at various time points after surgery to explore if there is field-change in the remaining colon, as well as to examine if persistent dysbiosis correlates with patient outcomes.
PURPOSE:To easily execute disease treatment by attaching medicine for disease treatment to a tissue paper which is formed in a folded shape or laminated shape. CONSTITUTION:A tissue paper 1 is composed of a paper 2 and disease treatment medicine 3 and the paper 2 is composed of a paper material, which is comparatively soft, to have hygroscopicity. Then, the paper 2 is formed with the rectangular shape paper of a prescribed size and the disease treatment medicine 3 is coated on the surface of the paper 2. Then, the paper 2 is folded and received in the small transparent bag of vinyl, etc. The disease treatment medicine 3 is the medicine for pollinosis treatment. Since a nose is blown with the tissue paper 1, the same effect as the treatment by the spray of the medicine for pollinosis treatment is generated and the effect of the treatment can be enough obtained.
PURPOSE: Digistain Index (DI), measured using an inexpensive mid-infrared spectrometer, reflects the level of aneuploidy in unstained tissue sections and correlates with tumor grade. We investigated whether incorporating DI with other clinicopathological variables could predict outcomes in patients with early breast cancer.
METHODS: DI was calculated in 801 patients with hormone receptor-positive, HER2-negative primary breast cancer and ≤ 3 positive lymph nodes. All patients were treated with systemic endocrine therapy and no chemotherapy. Multivariable proportional hazards modeling was used to incorporate DI with clinicopathological variables to generate the Digistain Prognostic Score (DPS). DPS was assessed for prediction of 5- and 10-year outcomes (recurrence, recurrence-free survival [RFS] and overall survival [OS]) using receiver operating characteristics and Cox proportional hazards regression models. Kaplan-Meier analysis evaluated the ability of DPS to stratify risk.
RESULTS: DPS was consistently highly accurate and had negative predictive values for all three outcomes, ranging from 0.96 to 0.99 at 5 years and 0.84 to 0.95 at 10 years. DPS demonstrated statistically significant prognostic ability with significant hazard ratios (95% CI) for low- versus high-risk classification for RFS, recurrence and OS (1.80 [CI 1.31-2.48], 1.83 [1.32-2.52] and 1.77 [1.28-2.43], respectively; all P < 0.001).
CONCLUSION: DPS showed high accuracy and predictive performance, was able to stratify patients into low or high-risk, and considering its cost and rapidity, has the potential to offer clinical utility.
<P>PROBLEM TO BE SOLVED: To provide a health food effective for preventing the excessive intake of cadmium and exhibiting antineoplastic activity and provide a method for easily producing the health food at a low cost.  <P>SOLUTION: The antineoplastic health food is composed of dried and pulverized fruit body of Agaricus blazei Murrill containing cadmium and ≥5 pts. wt. of free cyanogen based on 100 pts. wt. of the cadmium. The antineoplastic health food containing ≥5 pts. wt. of free cyanogen based on 100 pts. wt. of cadmium as an inevitable impurity in the final product is produced by using dried fruit body of Agaricus blazei Murrill having a cadmium concentration of ≤4 ppm as a raw material and drying and pulverizing the fruit body.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: Fibrotic interstitial lung disease (fILD) is characterised primarily by impaired lung function and quality of life. The present study investigated whether oxygen therapy could improve exercise capacity among patients with fILD.
METHODS: Previously published randomised controlled trials (RCTs) were surveyed. A systematic review and meta-analysis was conducted to evaluate the effectiveness of oxygen therapy in improving the exertional capacity of patients with fILD. The primary outcome was peripheral oxygen saturation (SpO2) during exercise. The effects of oxygen therapy on fatigue, dyspnoea, heart rate, and exercise duration or distance were also analysed.
RESULTS: Fourteen RCTs involving 370 patients were included. Oxygen therapy improved SpO2 during exercise (mean difference, MD = 6.26 %), exercise duration (MD = 122.15 s), fatigue (standard mean difference, SMD = -0.30), and dyspnoea (MD = -0.75 Borg score units). High-flow oxygen systems tended to be more effective than low-flow systems in improving exercising SpO2, duration, fatigue, dyspnoea, and heart rate. High-flow nasal cannulas (HFNCs) yielded better outcomes regarding SpO2 and fatigue than did high-flow Venturi masks (MD = 1.60 % and MD = -1.19 Borg score units, respectively). No major adverse events were reported.
CONCLUSION: The evidence from RCTs supports the short-term use of oxygen supplementation to improve SpO2, exercise capacity, fatigue, and dyspnoea among patients with fILD. Further analyses demonstrates that HFNCs yield more favourable outcomes, yet not reaching statistical significance except for improving SpO2 and fatigue. However, the long-term effects of oxygen therapy on quality of life and mortality remain unclear.
The invention relates to a medicine for treating kidney calculi, which takes herba lysimachiae, corn beard, lygodium japonicum, raw oysters, malva verticillata L, etc. as raw materials which are boiled out with water. And the decoction solution is concentrated and dried to be made into capsules. The medicine of the invention can eliminate and reinforce simultaneously and activate blood circulation to dissipate blood stasis and is applied to the treatment of kidney calculi and calculus in urinary system. The medicine can also prevent calculi infection, can relieve the pains of patients, protect renal function, try to remove calculi and prevent the recurrence. Clinical 586 cases of the patients with kidney calculi validates that the total effective rate of the medicine of the invention reaches to 95.9 percent and the drug of the invention has the advantages of good taste, fast efficacy and less side effects.
The samples are collected from patients referred to colposcopy because of prior cervical abnormalities. The patient takes at home two urine samples with the Colli-Pee device (a device that allows to collect first-void urine), the day before the visit to the colposcopy centre. At the colposcopy centre, two vaginal self-samples are taken by the patient herself: one with a cotton swab and a second with a plastic brush. Finally, the gynecologist takes a cervical Pap smear with a Cervex-Brush Combi.

A real-time PCR test will be used to detect DNA of high-risk HPV types. It is possible that in the future also other tests will be validated on these samples. The colposcopy and histological findings will be used as the gold standard. The main purpose of the study is to assess the relative diagnostic tests accuracy of hrHPV testing on self- and urine samples compared to hrHPV testing on cervical samples taken by a clinician. Furthermore, the participating women will receive also a questionnaire which can give insights into the attitudes and preferences of the women with regard to the self-sampling devices.
Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.